Interleukin‑6 signaling blockade treatment for cytokine release syndrome in COVID‑19 (Review) | Zendy

Jiajie Chen | Zendy; Lina Zhang | Zendy; Hu Hou | Zendy; Lingqing Xu | Zendy; Kunmei Ji | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Interleukin‑6 signaling blockade treatment for cytokine release syndrome in COVID‑19 (Review)

Author(s) -

Jiajie Chen,

Lina Zhang,

Hu Hou,

Lingqing Xu,

Kunmei Ji

Publication year - 2020

Publication title -

experimental and therapeutic medicine

Language(s) - English

Resource type - Journals

eISSN - 1792-1015

pISSN - 1792-0981

DOI - 10.3892/etm.2020.9456

Subject(s) - blockade , cytokine , cytokine release syndrome , covid-19 , immunology , medicine , oncogene , interleukin , signal transduction , apoptosis , cancer research , molecular medicine , interleukin 2 , receptor , immunotherapy , cancer , biology , cell cycle , immune system , microbiology and biotechnology , disease , chimeric antigen receptor , infectious disease (medical specialty) , biochemistry

A severe immune response in patients with coronavirus disease 2019 (COVID-19) can cause a potentially lethal unconstrained inflammatory cytokine storm, known as cytokine release syndrome (CRS). The present study provides an overview of the biology underlying CRS and how targeted inhibition of interleukin (IL)-6 signaling may improve outcomes and the survival of patients suffering from COVID-19. Preliminary clinical results have indicated that antagonism of the IL-6 receptor (IL-6R), including with the FDA-approved humanized monoclonal antibody tocilizumab, can improve the outcomes of patients with severe or critical COVID-19 while maintaining a good safety profile. The available clinical data support the expansion of clinical trials using IL-6R targeting inhibitors for severe and critical COVID-19 treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research